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M ANY PHARMACIES HAVE imple-mented or considered implementing cleanroom automation or compound-
ing systems.1
Intravenous (IV) admixture automation is 
one of the newest areas of technology that 
has been applied to pharmacy workflow. 
Manufacturers tout systems for reducing 
errors reaching patients.2-4 Clinical literature 
supports that cleanroom technology can 
aid in patient safety.5,6 Errors that occur 
during sterile product compounding can 
have significant consequences, from minor 
harm to the death of patients and expensive 
lawsuits.7-9 Pharmacies have attempted to 
achieve the following goals as part of tech 
justification: reducing errors and improving 
accuracy, productivity, and workflow. Based 
on a justification for financial approval, 
here are pre- and postimplementation 
checklists for evaluating or upgrading 
existing automation in the cleanroom and 
for justifying the investment, including 
financial considerations, medication safety, 
productivity, and quality.
Preimplementation Assessment
Financial justification. Most facilities 
typically require some form of financial 
analysis and justification for capital expendi-
tures. This information typically includes cost 
avoidance for medication errors, potential 
staffing adjustments, ability to handle growth, 
consumables for the automated systems, 
and potential reduction in outsourcing. Our 
previous study suggested productivity and 
safety were overriding reasons for imple-
mentation, but a large number of facilities 
still required financial analysis.10 In addition, 
vendors often publicize that these systems 
reduce waste by creating more just-in-time 
dose preparation, decreasing lost and missing 
doses, and reducing rejected product and 
remakes.2-4  Reporting tools for metrics and 
monitoring to document achievement of 
stated goals is also a consideration.
Medication safety. Most vendors project a 
reduction in medication errors pre-implemen-
tation. Error reduction can be achieved through 
automated calculations, barcode verifica-
tion of ingredients, and use of standardized 
preparation steps.11 It is important to identify 
upfront how one will measure medication 
safety pre- and post-implementation as it 
relates to the automation technology. A brief 
meeting with the chief financial officer can 
help firm up how savings will be counted on 
analysis of the project.  
Promote dose preparation accuracy 
and safety. Cleanroom automation is 
advertised as highly accurate with automated 
calculations, standardized concentrations 
and preparation steps, which yields more 
consistently accurate results than the manual 
compounding process.2-4 Pharmacists  evalu-
ating these systems should request evidence-
based data supporting any accuracy claims 
made by vendors related to the technology 
and validate it with a currently installed 
client. Before implementation, pharmacies 
should evaluate any additional regulations 
or governing approvals that are required, 
including being compliant for USP Chapter 
<797>. Consideration should be given to 
identify quality control processes and addi-
tional required equipment.
 Productivity. Pharmacy administrators 
must identify if staff workflow redesign 
is an implementation goal or part of the 
justification. The impact on pharmacist 
checking time is also a consideration, as 
many systems tout remote verification and 
suggest freed-up time. If increased volume 
is a concern, a metric should be identified to 
track any associated changes in staffing from 
baseline. Some vendors tout the reporting 
capabilities of their systems to allow anal-
ysis and trending of workloads and  
productivity.2-4 
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Additional items. Other matters to be 
addressed before implementation include 
compounding outside the automation, drug 
inventory storage, order entry and verification, 
policies and procedures for compounding 
sterile preparations in automated systems, 
preparation of source/bulk containers, 
product labeling and staff management, 
and workflow.11,12
Postimplementation Analysis
Facilities should report results and obtain a 
baseline for any metrics prior to implemen-
tation and associate reporting with the return 
on investment (ROI). Typically, results should 
be reported on an annual basis. Comparing 
annual metrics yields insight to improvements 
achieved with technology. Metrics to review 
include:
•  Accuracy. Work with vendors to identify 
quality control procedures and measure 
accuracy at the recommended intervals 
and document results. If internal data 
exist, they should be compared with the 
automated systems.
•  Financial. In our previous study, almost 
half the subjects indicated no savings were 
realized or documented related to IV room 
automation.10 This issue is likely because a 
precise measurement tool was not adopted 
with baseline information before imple-
mentation. Also, including a parameter to 
monitor missing doses or product remakes 
could yield significant savings to identify 
impact on supply cost reduction.
•  Medication safety. Any documented 
improvements should be made with a 
specified error rate reduction associated 
with IV compounding.
•  Productivity. A baseline volume that 
accounts for seasonal variation for the 
cleanroom should be identified and used 
for comparison. This baseline should 
identify staffed hours, as well as a measur-
able volume.
Implications
IV room automation justification and anal-
ysis can be a complex process. Facilities that 
have implemented IV room automation have 
overwhelmingly indicated that there was not 
an ongoing assessment for justification of 
the achievement of the ROI.10 Identifying the 
metrics that will be assessed before implemen-
tation and an associated reporting plan for the 
institution’s specific goals with this technology 
are critical to justifying an ROI and docu-
menting improvements of this technology. ■
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